Overview

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Status:
Terminated
Trial end date:
2017-08-25
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, open label, uncontrolled, non-interventional, single arm study to measure treatment satisfaction of relapsing remitting MS (RRMS) participants on Rebif after discontinuing initial first-line treatment.
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Collaborator:
Merck B.V., Netherlands
Treatments:
Interferon beta-1a